RBC Capital raised the firm’s price target on Gilead (GILD) to $98 from $96 and keeps a Sector Perform rating on the shares. The company’s Q2 results looked “solid”, with beats across key HIV/PrEP franchises and misses coming from programs less important to long-term growth, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $128 from $125 at Oppenheimer
- Gilead price target raised to $130 from $120 at BMO Capital
- Gilead price target raised to $143 from $135 at Morgan Stanley
- Assembly Biosciences reports interim results from phase 1b study of ABI-5366
- Gilead price target raised to $112 from $108 at UBS